ACM
TXMD icon

ADAR1 Capital Management’s TherapeuticsMD TXMD Stock Holding History

ADAR1 Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Buy
342,447
+133,237
+64% +$275K 0.03% 185
2026
Q1 		$423K Hold
209,210
– – 0.02% 215
2025
Q4 		$341K Hold
209,210
– – 0.03% 206
2025
Q3 		$225K Hold
209,210
– – 0.02% 175
2025
Q2 		$243K Sell
209,210
-60,950
-23% -$73.9K 0.04% 149
2025
Q1 		$250K Hold
270,160
– – 0.05% 138
2024
Q4 		$232K Hold
270,160
– – 0.05% 153
2024
Q3 		$448K Hold
270,160
– – 0.07% 122
2024
Q2 		$435K Sell
270,160
-2,000
-0.7% -$4.04K 0.08% 107
2024
Q1 		$623K Hold
272,160
– – 0.14% 75
2023
Q4 		$612K Buy
+272,160
New +$657K 0.22% 56

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ADAR1 Capital Management's TXMD Position: Q2 2026 in Review

ADAR1 Capital Management increased its TherapeuticsMD (TXMD) stake by 64% in Q2 2026, buying an estimated $275K and bringing the position to 342,447 shares worth $757K. The position accounts for 0.03% of the portfolio, ranked #185.

ADAR1 Capital Management first reported a position in TXMD in Q4 2023 and has held it in 11 quarters since. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • ADAR1 Capital Management held 342,447 shares of TherapeuticsMD worth $757K as of Q2 2026.
  • ADAR1 Capital Management bought 133,237 TherapeuticsMD shares in Q2 2026, an estimated $275K.
  • TherapeuticsMD made up 0.03% of ADAR1 Capital Management's portfolio in Q2 2026, its #185 holding.
  • ADAR1 Capital Management first reported a position in TherapeuticsMD in Q4 2023 and has held it in 11 quarters since.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.